Home And Outpatient Respiratory Care Will Expand Market Opportunities

Published
01 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$11.00
29.5% undervalued intrinsic discount
15 Aug
US$7.75
Loading
1Y
-38.0%
7D
3.9%

Author's Valuation

US$11.0

29.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on10 Aug 25
Fair value Decreased 5.71%

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).

Shared on01 May 25
Fair value Increased 38%

Shared on24 Apr 25
Fair value Decreased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 18%